Real Labs, Actual Decisions With Actionable Six Sigma Metrics
Accessibility Statement Skip Navigation
QuidelOrtho Announces Featured ADLM Session
SAN DIEGO, July 17, 2025 /PRNewswire/ — How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagnostics & Laboratory Medicine (ADLM) meeting, QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) and a panel of experts will share how QuidelOrtho’s Six Sigma tools and real lab data can drive quality outcomes.
ADLM Session Details:
Angela Armato, Core Lab Manager, United Health Services and UHS Hospitals
Gilles Attipoe, Director of Laboratory Services, St. Peter’s University Hospital
Dr. Bremansu Osa-Andrews, Medical Director of Clinical Chemistry and Clinical Assistant Professor, University of Florida PathLab
Dr. Jared Jaeger, Clinical Science Liaison, QuidelOrtho, Moderator
Session Title: |
Real Labs, Real Decisions with Actionable Six Sigma Metrics |
When: |
Tuesday, July 29, 2025 |
Where: |
McCormick Convention Center Chicago, IL Exhibit Hall, Theater 1 |
Time: |
2:45 p.m. – 3:45 p.m. CT |
Registration: |
Space is limited. ADLM attendees can register for the session using |
Real Labs, Real Decisions With Actionable Six Sigma Metrics Panelists:
Dr. Jared JaegerClinical Science Liaison
QuidelOrtho
Moderator
Dr. Bremansu Osa-AndrewsMedical Director of Clinical
Chemistry and Clinical Assistant Professor
University of Florida PathLab
Gilles AttipoeDirector of Laboratory Services
St. Peter’s University Hospital
Angela ArmatoCore Lab Manager
United Health Services and UHS Hospitals
To learn more about Six Sigma and the value of using real-world data listen to “Sigma Metrics and the Value of Real World Evidence.” In this podcast, QuidelOrtho data scientist Johanna Miller discusses how Six Sigma metrics are being adapted for the clinical laboratory.
Unable to attend ADLM? Register to watch a recording of the session: https://www2.na-ma.quidelortho.com/25-adlm-workshop-subscribe.
About QuidelOrthoQuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact: Juliet Cunningham Vice President, Investor Relations |
Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications |
SOURCE QuidelOrtho Corporation
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+Newsrooms &Influencers
9k+Digital MediaOutlets
270k+JournalistsOpted In